Write what you believe about your stocks; every morning the cited record grades it: supported, challenged, or untouched. Never opinions.

Development · 3 Nov 2026

MANKIND, full dossier

Mankind Pharma posted 17 per cent Y-o-Y sales growth in Q2FY27, while Ebitda grew faster at 27 per cent Y-o-Y, resulting in 210 bps Y-o-Y margin expansion to 27 per cent.

1 publisher has reported this development. Each act of reporting is below, cited.

The record

Mankind Pharma posted 17 per cent Y-o-Y sales growth in Q2FY27, while Ebitda grew faster at 27 per cent Y-o-Y, resulting in 210 bps Y-o-Y margin expansion to 27 per cent.

A single act of reporting so far, corroborating sources join this record as they publish.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.